What is the current valuation of the US breast cancer market?

The US breast cancer market was valued at 1113.13 USD Million in 2024. Read More

What is the projected market size for the US breast cancer market by 2035?

The market is projected to reach 2936.84 USD Million by 2035. Read More

What is the expected CAGR for the US breast cancer market during the forecast period?

The expected CAGR for the US breast cancer market from 2025 to 2035 is 9.22%. Read More

Which companies are the key players in the US breast cancer market?

Key players include Roche, Pfizer, AstraZeneca, Novartis, Merck & Co, Bristol-Myers Squibb, Gilead Sciences, Eli Lilly and Company, and Amgen. Read More

What are the primary diagnosis methods used in the US breast cancer market?

Primary diagnosis methods include Mammography, Ultrasound, Magnetic Resonance Imaging, Biopsy, and Genetic Testing. Read More

How does the market perform in terms of treatment types for breast cancer?

The market segments for treatment types include Surgery, Radiation Therapy, Chemotherapy, Hormonal Therapy, and Targeted Therapy. Read More

What are the market valuations for different stages of breast cancer?

Market valuations for stages include Stage 0 at 50.0 to 130.0 USD Million, Stage I at 200.0 to 500.0 USD Million, Stage II at 300.0 to 800.0 USD Million, Stage III at 350.0 to 900.0 USD Million, and Stage IV at 213.13 to 606.84 USD Million. Read More

How do patient demographics influence the US breast cancer market?

Patient demographics are segmented by Age Group, Ethnicity, Socioeconomic Status, Genetic Predisposition, and Family History. Read More

What healthcare settings are involved in the US breast cancer market?

Healthcare settings include Hospitals, Outpatient Clinics, Specialized Cancer Centers, Home Healthcare, and Palliative Care. Read More

What trends are anticipated in the US breast cancer market by 2035?

The market is likely to expand significantly, driven by advancements in treatment and diagnosis, alongside increasing awareness and screening initiatives. Read More

US Breast cancer Market

ID: MRFR/Pharma/16386-HCR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

United States Breast cancer Market Research Report: Size, Share, Trend Analysis - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Diagnosis Method (USD Million)
  1. 4.1.1 Mammography
  2. 4.1.2 Ultrasound
  3. 4.1.3 Magnetic Resonance Imaging
  4. 4.1.4 Biopsy
  5. 4.1.5 Genetic Testing
2. 4.2 Healthcare, BY Treatment Type (USD Million)
  1. 4.2.1 Surgery
  2. 4.2.2 Radiation Therapy
  3. 4.2.3 Chemotherapy
  4. 4.2.4 Hormonal Therapy
  5. 4.2.5 Targeted Therapy
3. 4.3 Healthcare, BY Stage of Cancer (USD Million)
  1. 4.3.1 Stage 0
  2. 4.3.2 Stage I
  3. 4.3.3 Stage II
  4. 4.3.4 Stage III
  5. 4.3.5 Stage IV
4. 4.4 Healthcare, BY Patient Demographics (USD Million)
  1. 4.4.1 Age Group
  2. 4.4.2 Ethnicity
  3. 4.4.3 Socioeconomic Status
  4. 4.4.4 Genetic Predisposition
  5. 4.4.5 Family History
5. 4.5 Healthcare, BY Healthcare Setting (USD Million)
  1. 4.5.1 Hospital
  2. 4.5.2 Outpatient Clinic
  3. 4.5.3 Specialized Cancer Center
  4. 4.5.4 Home Healthcare
  5. 4.5.5 Palliative Care
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Pfizer (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 AstraZeneca (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Merck & Co (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Bristol-Myers Squibb (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Gilead Sciences (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Eli Lilly and Company (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Amgen (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY DIAGNOSIS METHOD
3. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
4. 6.4 US MARKET ANALYSIS BY STAGE OF CANCER
5. 6.5 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6. 6.6 US MARKET ANALYSIS BY HEALTHCARE SETTING
7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF HEALTHCARE
10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
13. 6.13 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 (% SHARE)
14. 6.14 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
15. 6.15 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
16. 6.16 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
17. 6.17 HEALTHCARE, BY STAGE OF CANCER, 2024 (% SHARE)
18. 6.18 HEALTHCARE, BY STAGE OF CANCER, 2024 TO 2035 (USD Million)
19. 6.19 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
20. 6.20 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Million)
21. 6.21 HEALTHCARE, BY HEALTHCARE SETTING, 2024 (% SHARE)
22. 6.22 HEALTHCARE, BY HEALTHCARE SETTING, 2024 TO 2035 (USD Million)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DIAGNOSIS METHOD, 2026-2035 (USD Million)
  2. 7.2.2 BY TREATMENT TYPE, 2026-2035 (USD Million)
  3. 7.2.3 BY STAGE OF CANCER, 2026-2035 (USD Million)
  4. 7.2.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  5. 7.2.5 BY HEALTHCARE SETTING, 2026-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Healthcare Market Segmentation

Healthcare By Diagnosis Method (USD Million, 2022-2035)

Mammography
Ultrasound
Magnetic Resonance Imaging
Biopsy
Genetic Testing

Healthcare By Treatment Type (USD Million, 2022-2035)

Surgery
Radiation Therapy
Chemotherapy
Hormonal Therapy
Targeted Therapy

Healthcare By Stage of Cancer (USD Million, 2022-2035)

Stage 0
Stage I
Stage II
Stage III
Stage IV

Healthcare By Patient Demographics (USD Million, 2022-2035)

Age Group
Ethnicity
Socioeconomic Status
Genetic Predisposition
Family History

Healthcare By Healthcare Setting (USD Million, 2022-2035)

Hospital
Outpatient Clinic
Specialized Cancer Center
Home Healthcare
Palliative Care

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”